The study entitled, “TSPYL5 suppresses p53 levels and function by physical interaction with USP7,” was published today in Nature Cell Biology.
The Sequenom Center for Molecular Medicine has authorized commencement of a pivotal clinical validation study.
Cepheid announced the release of Xpert Flu as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices.
Ralph Taylor has been promoted to the role of executive VP, marketing, business development, and medical/scientific affairs; and Robert Degnan to executive VP, commercial operations.
The vast majority of parents who tested positive for a genetic mutation that increases the risk of melanoma support genetic testing of their children or grandchildren.
The New York State Department of Health has issued Pathwork Diagnostics a clinical laboratory permit and approved the offering of the company’s Tissue of Origin testing service to New York State residents.
Thermo Fisher Scientific Inc has completed the acquisition of TKA Wasseraufbereitungssysteme GmbH.
Exagen Diagnostics Inc has been awarded $400,000 in funding under the IRS Qualifying Therapeutic Discovery Project (QTDP) program.
Nearly one third of pregnant women are not being screened by a simple laboratory test for gestational diabetes mellitus (gestational diabetes).
The Spartan RX CYP2C19 is a noninvasive DNA testing system that enables physicians to tailor treatments based on a patients genotype.